Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLOWTUSS vs ACETAMINOPHEN, ASPIRIN AND CAFFEINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
FLOWTUSS (guaifenesin) is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity and facilitating clearance.
Acetaminophen: weak COX-1/2 inhibitor, analgesic and antipyretic through central action; Aspirin: irreversible COX-1/2 inhibitor, anti-inflammatory, analgesic, antipyretic, antiplatelet; Caffeine: adenosine receptor antagonist, CNS stimulant, enhances analgesic effect.
Relief of productive cough associated with respiratory tract infections,Chronic obstructive pulmonary disease (COPD) exacerbations,Cystic fibrosis (off-label)
FDA-approved: Temporary relief of minor aches and pains (headache, muscle ache, toothache, backache, menstrual cramps), reduction of fever.,Off-label: None commonly accepted.
10 mg orally every 4-6 hours as needed for cough; maximum 60 mg/day.
1-2 tablets (250 mg acetaminophen, 250 mg aspirin, 65 mg caffeine per tablet) orally every 4-6 hours as needed for pain or fever; maximum 8 tablets per 24 hours.
Terminal elimination half-life is 4–6 hours in adults with normal renal function; prolonged to 8–12 hours in moderate renal impairment (Cr Cl 30–50 m L/min).
Acetaminophen: 2-4 hours (prolonged in liver disease); aspirin: 15-20 minutes (active metabolite salicylate: 2-3 hours at low doses, prolonged to 15-30 hours at high doses); caffeine: 3-6 hours (prolonged in pregnancy, liver disease).
Hepatic metabolism via oxidation and demethylation; primarily excreted renally as metabolites.
Acetaminophen: primarily hepatic via glucuronidation (UGT1A1, UGT1A6, UGT1A9), sulfation (SULT1A1), and minor CYP2E1 (toxic metabolite NAPQI); Aspirin: hydrolyzed to salicylate, further metabolized by conjugation (glycine, glucuronic acid) and oxidation; Caffeine: hepatic via CYP1A2 (major), CYP2E1, CYP3A4, N-acetyltransferase.
Renal elimination of unchanged drug accounts for 60–70%; hepatic metabolism (30–40%) with fecal excretion of metabolites via bile (20–25%) and urine (10–15%).
Acetaminophen: renal elimination of metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate 8%, unchanged 2%); aspirin: renal elimination of salicylate and metabolites (75% salicyluric acid, 10% glucuronides, 10% salicylate); caffeine: renal elimination of metabolites (paraxanthine, theobromine, theophylline; <3% unchanged). Total: >95% renal.
85–90% bound to albumin and alpha-1-acid glycoprotein.
Acetaminophen: 10-25% (albumin); aspirin: 80-90% (albumin, decreased at high doses); caffeine: 35% (albumin).
1.5–2.0 L/kg; indicates extensive tissue distribution (e.g., lungs, liver).
Acetaminophen: 0.9-1.0 L/kg; aspirin: 0.15-0.2 L/kg (low); caffeine: 0.6-0.8 L/kg. Reflects distribution into total body water.
Oral: 75–85% (first-pass metabolism accounts for 15–25% loss).
Acetaminophen: oral 85-98%; aspirin: oral 50-80% (due to first-pass hydrolysis); caffeine: oral ~100%.
e GFR 30-60 m L/min: 5 mg every 6 hours; e GFR <30 m L/min: 5 mg every 8 hours.
Contraindicated in severe renal impairment (Cr Cl <10 m L/min). For Cr Cl 10-50 m L/min: avoid aspirin component; consider alternative therapy. For Cr Cl >50 m L/min: no adjustment needed for acetaminophen; aspirin may require dose reduction or monitoring.
Child-Pugh Class B: 5 mg every 6 hours; Child-Pugh Class C: 2.5 mg every 8 hours.
Child-Pugh A: caution with acetaminophen (max 2 g/day) and avoid caffeine if severe. Child-Pugh B: avoid aspirin; reduce acetaminophen dose (max 2 g/day) and limit caffeine. Child-Pugh C: contraindicated due to aspirin and acetaminophen risk.
Children 2-6 years: 2.5 mg orally every 6 hours; 6-12 years: 5 mg orally every 6 hours; >12 years: same as adult.
Not recommended for children <12 years due to aspirin risk of Reye's syndrome. For adolescents ≥12 years: same as adult dosing: 1-2 tablets every 4-6 hours, max 8 tablets/24 hours.
Initial dose 5 mg every 6 hours; increase cautiously due to increased risk of dizziness and sedation.
Caution due to increased sensitivity to aspirin (GI bleeding, renal impairment) and caffeine (insomnia, tachycardia). Start at low end of dosing: 1 tablet every 6 hours; monitor renal function and avoid long-term use.
None.
Reye syndrome warning: Aspirin should not be used in children or teenagers with viral illnesses due to risk of Reye syndrome.
Avoid use with persistent or chronic cough (e.g., smoking, asthma, COPD) unless directed by a physician. Use caution in patients with renal impairment.
Hepatotoxicity (acetaminophen overdose), gastrointestinal bleeding (aspirin), Reye syndrome (aspirin in children with viral illness), cardiovascular risk (aspirin may increase bleeding), caffeine-related CNS stimulation, risk of dependence.
Hypersensitivity to guaifenesin or any component; concurrent use with other expectorants.
Hypersensitivity to any component; active peptic ulcer disease; bleeding disorders; severe hepatic impairment; children/adolescents with viral illness (Reye syndrome); third trimester of pregnancy (aspirin); concurrent use of other salicylates or NSAIDs; severe renal impairment.
No specific food interactions. Alcohol may increase CNS depressant effects (dizziness, sedation).
Alcohol increases risk of hepatotoxicity with acetaminophen and GI bleeding with aspirin. Caffeine-containing foods or beverages should be limited to avoid excessive caffeine intake. High-tyramine foods (e.g., aged cheeses, cured meats) may potentiate caffeine effects; no significant interaction documented.
FLOWTUSS contains guaifenesin and dextromethorphan. Guaifenesin is FDA pregnancy category C; animal studies show fetal abnormalities at high doses, but human data insufficient. Dextromethorphan is category C; limited human studies show no clear teratogenic risk, but high doses may cause fetal toxicity. Avoid in first trimester; use only if benefit outweighs risk in second and third trimesters.
First trimester: Aspirin is associated with increased risk of neural tube defects and cardiac malformations; acetaminophen is considered low risk but some studies suggest possible association with gastroschisis. Second trimester: Aspirin may increase risk of intracranial hemorrhage; acetaminophen and caffeine generally not linked to major malformations. Third trimester: Aspirin use is contraindicated due to risk of premature ductus arteriosus closure and oligohydramnios; high-dose acetaminophen may cause oligohydramnios; caffeine metabolism slows, but moderate intake appears safe; chronic high-dose caffeine may be associated with low birth weight.
Guaifenesin and dextromethorphan are excreted in breast milk in low amounts. M/P ratio not established for either. Use with caution; monitor infant for sedation or respiratory depression.
Acetaminophen: M/P ratio approximately 0.9; small amounts excreted; considered safe. Aspirin: M/P ratio variable, typically 0.12-0.42; avoid high doses due to risk of Reye's syndrome; single doses unlikely harmful. Caffeine: M/P ratio approximately 0.5-1.0; moderate intake (≤300 mg/day) considered safe; excessive intake may cause irritability in infant.
No standard dose adjustment recommended during pregnancy. Use lowest effective dose for shortest duration. Consider pharmacokinetic changes in pregnancy (increased clearance of dextromethorphan may require higher doses for efficacy, but safety limits apply).
Acetaminophen: No dose adjustment needed; standard dosing (650-1000 mg every 4-6 hours, max 3000 mg/day). Aspirin: Avoid doses >81 mg/day in third trimester; use lowest effective dose. Caffeine: Metabolism prolonged; limit to ≤200 mg/day (approximately 2 cups coffee).
FLOWTUSS (guaifenesin) is an expectorant that increases respiratory tract fluid secretion, reducing mucus viscosity. Onset of action is 30-60 minutes. Maximum effect requires adequate hydration (8-10 glasses of water daily). Not recommended for chronic cough due to smoking, asthma, or emphysema. Avoid use in patients with persistent cough lasting >1 week or accompanied by fever, rash, or headache. May cause dizziness; caution when driving.
Acetaminophen, aspirin, and caffeine combination is used for mild to moderate pain and fever reduction. Aspirin component provides anti-inflammatory effects; caution in patients with bleeding disorders or those on anticoagulants due to increased bleeding risk. Acetaminophen hepatotoxicity risk with doses >4g/day or in liver disease. Caffeine may cause insomnia, tremor, or palpitations; avoid in patients with anxiety disorders. Reye syndrome risk with aspirin use in children with viral illnesses. Monitor renal function in elderly or dehydrated patients.
Drink plenty of water to help loosen mucus.,Do not take more than 6 doses in 24 hours.,Discontinue and consult doctor if cough persists >7 days or if fever, rash, or headache develop.,Avoid alcohol; may increase dizziness.,Do not use for chronic cough from smoking or asthma without medical advice.
Do not exceed recommended dose; acetaminophen overdose can cause liver damage.,Avoid alcohol while taking this medication.,Do not use in children or teenagers with viral illnesses due to Reye syndrome risk.,May cause stomach upset; take with food or milk.,Limit caffeine intake from other sources when using this medication.
No interactions on record
"Triamterene, a potassium-sparing diuretic, can inhibit the hepatic metabolism of caffeine by competing for cytochrome P450 (CYP) 1A2, the primary enzyme responsible for caffeine clearance. This leads to increased plasma caffeine concentrations and prolonged caffeine half-life, potentially causing caffeine toxicity manifesting as nervousness, insomnia, tachycardia, and diuresis enhancement. Patients may experience exaggerated stimulant effects and increased risk of cardiac arrhythmias when combining these agents."
"Caffeine inhibits the metabolism of sulfadiazine by competitively antagonizing cytochrome P450 (CYP) enzymes, particularly CYP1A2, leading to increased plasma concentrations of sulfadiazine. This elevates the risk of dose-dependent adverse effects, including crystalluria, nephrotoxicity, and hypersensitivity reactions. The interaction may also reduce the therapeutic efficacy of sulfadiazine due to altered pharmacokinetics."
"Caffeine inhibits the cytochrome P450 enzyme CYP2C9, which is primarily responsible for the metabolism of losartan to its active metabolite E-3174. This inhibition can lead to increased plasma concentrations of losartan and decreased formation of the active metabolite, potentially reducing losartan's antihypertensive efficacy. The clinical outcome may be suboptimal blood pressure control in patients consuming high amounts of caffeine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLOWTUSS vs ACETAMINOPHEN, ASPIRIN AND CAFFEINE, answered by our medical review team.
FLOWTUSS is a Expectorant that works by FLOWTUSS (guaifenesin) is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity and facilitating clearance.. ACETAMINOPHEN, ASPIRIN AND CAFFEINE is a NSAID / Antiplatelet that works by Acetaminophen: weak COX-1/2 inhibitor, analgesic and antipyretic through central action; Aspirin: irreversible COX-1/2 inhibitor, anti-inflammatory, analgesic, antipyretic, antiplatelet; Caffeine: adenosine receptor antagonist, CNS stimulant, enhances analgesic effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLOWTUSS and ACETAMINOPHEN, ASPIRIN AND CAFFEINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLOWTUSS is: 10 mg orally every 4-6 hours as needed for cough; maximum 60 mg/day.. The standard adult dose of ACETAMINOPHEN, ASPIRIN AND CAFFEINE is: 1-2 tablets (250 mg acetaminophen, 250 mg aspirin, 65 mg caffeine per tablet) orally every 4-6 hours as needed for pain or fever; maximum 8 tablets per 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLOWTUSS and ACETAMINOPHEN, ASPIRIN AND CAFFEINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLOWTUSS is classified as Category C. FLOWTUSS contains guaifenesin and dextromethorphan. Guaifenesin is FDA pregnancy category C; animal studies show fetal abnormalities at high doses, but human data insufficient. Dex. ACETAMINOPHEN, ASPIRIN AND CAFFEINE is classified as Category D/X. First trimester: Aspirin is associated with increased risk of neural tube defects and cardiac malformations; acetaminophen is considered low risk but some studies suggest possible . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.